Mehta Vimal — SEC Form 4 filings
SEC reporting owner CIK 1733369. 18 Form 4 filings on record with FilingPulse; latest filed 2026-06-17.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2024-04-08 to 2026-06-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 13 legs across 6 filings — 1,459,414 shares, $445,304 total (shares × price as filed on priced legs).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 48.
- Largest priced transaction: sale of 126,014 shares @ $1.63 ($205,516) in BioXcel Therapeutics, Inc., filed 2024-06-06.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | CEO and President, Director | 18 | — | 13 legs · 1,459,414 sh · $445,304 | 48 |
Form 4 filings — Mehta Vimal
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-17 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 219 · Option exercise (M): 219 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 49,758 · Sale (S): 19,419 @ $1.09 · Option exercise (M): 49,758 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 18,000 · Option exercise (M): 18,000 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 164 · Option exercise (M): 219 · Option exercise (M): 164 (derivative) @ $0 · Option exercise (M): 219 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 199,032 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 164 · Option exercise (M): 219 · Option exercise (M): 164 (derivative) @ $0 · Option exercise (M): 219 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 163 · Option exercise (M): 219 · Option exercise (M): 163 (derivative) @ $0 · Option exercise (M): 219 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-07-22 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 15,625 | EDGAR |
| 2025-06-16 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 163 · Option exercise (M): 219 · Option exercise (M): 163 (derivative) @ $0 · Option exercise (M): 219 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 6,250 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 162 · Option exercise (M): 217 · Option exercise (M): 162 (derivative) @ $0 · Option exercise (M): 217 (derivative) @ $0 | EDGAR |
| 2025-01-10 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 660,000 (derivative) @ $0 | EDGAR |
| 2024-12-17 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 2,610 · Option exercise (M): 3,500 · Sale (S): 983 @ $0.36 · Sale (S): 2,134 @ $0.36 · Option exercise (M): 2,610 (derivative) @ $0 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2024-09-17 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 2,609 · Option exercise (M): 3,500 · Sale (S): 832 @ $0.69 · Sale (S): 1,150 @ $0.69 · Option exercise (M): 2,609 (derivative) @ $0 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 2,609 · Option exercise (M): 3,500 · Sale (S): 2,134 @ $1.28 · Option exercise (M): 2,609 (derivative) @ $0 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | BioXcel Therapeutics, Inc. (BTAI) jointly with BioXcel Holdings, Inc., BioXcel LLC | Sale (S): 609,221 · Sale (S): 283,123 · Sale (S): 283,122 · Sale (S): 126,014 @ $1.63 · Sale (S): 126,014 @ $1.58 · Sale (S): 120 (derivative) | EDGAR |
| 2024-04-08 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 2,610 · Option exercise (M): 14,000 · Sale (S): 829 @ $2.62 · Sale (S): 4,439 @ $2.62 · Option exercise (M): 2,610 (derivative) @ $0 · Option exercise (M): 14,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1733369 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →